Zacks: Brokerages Expect MEDNAX Inc (MD) Will Announce Earnings of $0.84 Per Share
Equities analysts predict that MEDNAX Inc (NYSE:MD) will report earnings of $0.84 per share for the current fiscal quarter, according to Zacks. Seven analysts have issued estimates for MEDNAX’s earnings. The lowest EPS estimate is $0.75 and the highest is $0.88. MEDNAX posted earnings per share of $0.75 during the same quarter last year, which indicates a positive year over year growth rate of 12%. The firm is scheduled to announce its next earnings results on Thursday, April 19th.
On average, analysts expect that MEDNAX will report full-year earnings of $4.22 per share for the current fiscal year, with EPS estimates ranging from $4.02 to $4.30. For the next fiscal year, analysts anticipate that the firm will report earnings of $4.47 per share, with EPS estimates ranging from $4.32 to $4.65. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover MEDNAX.
MEDNAX (NYSE:MD) last released its quarterly earnings data on Thursday, February 8th. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.04. The firm had revenue of $910.82 million for the quarter, compared to the consensus estimate of $884.55 million. MEDNAX had a net margin of 9.26% and a return on equity of 10.10%. The firm’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.00 earnings per share.
MEDNAX (MD) traded up $0.01 during mid-day trading on Friday, reaching $57.58. 1,264,247 shares of the company were exchanged, compared to its average volume of 1,044,742. The stock has a market capitalization of $5,400.77, a P/E ratio of 16.69, a P/E/G ratio of 1.43 and a beta of 0.26. MEDNAX has a 52-week low of $40.56 and a 52-week high of $71.26. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.60.
In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total value of $154,740.00. Following the sale, the insider now owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.40% of the stock is owned by corporate insiders.
Several large investors have recently bought and sold shares of the company. Envestnet Asset Management Inc. raised its position in shares of MEDNAX by 6.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 49,590 shares of the company’s stock valued at $2,650,000 after buying an additional 3,059 shares during the last quarter. William Blair Investment Management LLC raised its position in shares of MEDNAX by 12.5% in the fourth quarter. William Blair Investment Management LLC now owns 12,749 shares of the company’s stock valued at $681,000 after buying an additional 1,421 shares during the last quarter. MetLife Investment Advisors LLC acquired a new position in shares of MEDNAX in the fourth quarter valued at approximately $3,167,000. Endurant Capital Management LP raised its position in shares of MEDNAX by 3.0% in the fourth quarter. Endurant Capital Management LP now owns 181,717 shares of the company’s stock valued at $9,711,000 after buying an additional 5,317 shares during the last quarter. Finally, Macquarie Group Ltd. raised its position in shares of MEDNAX by 36.1% in the fourth quarter. Macquarie Group Ltd. now owns 4,900 shares of the company’s stock valued at $262,000 after buying an additional 1,300 shares during the last quarter. 98.89% of the stock is owned by institutional investors and hedge funds.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.